A landmark cardiovascular trial found that a purified form of omega-3 cut major heart events by 25 percent. A larger, better-funded trial testing standard fish oil in a general population found almost nothing.
Both studies ran around the same time, in similar-aged adults, using similar cardiovascular endpoints. Both were large, randomized, and published in a top medical journal.
The gap between their results is the real story behind omega-3 fatty acids, and it explains why the supplement aisle is full of confident claims that the underlying research does not fully back.
The trial that split the omega-3 story in two
In 2019, researchers published results from REDUCE-IT, a trial led by Deepak Bhatt, a cardiologist then at Brigham and Women’s Hospital. It tested a highly purified, prescription-strength dose of EPA, one of the two main omega-3 fatty acids, in over 8,000 people who already had heart disease or diabetes with elevated triglycerides.
The result was striking. Patients taking 4 grams a day of purified EPA had a 25 percent lower rate of cardiovascular death, heart attack, or stroke compared to placebo.
That same year, the VITAL trial, led by JoAnn Manson at Harvard, published results from nearly 26,000 healthy adults given a much lower dose, roughly 1 gram a day of a combined EPA and DHA supplement, the kind sold in most drugstores. The primary finding was no significant reduction in major cardiovascular events for the group as a whole.
Two well-designed trials, two very different doses and populations, two nearly opposite headlines. That contrast is why cardiologists still argue about what a bottle of fish oil actually does for an otherwise healthy person.
Dose and purity, not just fish oil, decide the outcome
The instinct to lump every omega-3 study into one conclusion is where most confusion starts. REDUCE-IT used a dose roughly four times higher than what is in a typical over-the-counter capsule, in people who were already sick.
VITAL used a fraction of that dose in people who were mostly healthy, many of whom already ate fish regularly. Lower dose, lower baseline risk, smaller effect to detect statistically.
There is also an unresolved controversy specific to REDUCE-IT: its placebo was mineral oil, which some researchers argue may have slightly worsened cholesterol markers in the control group and inflated the apparent benefit of the EPA arm. It does not erase the result, but it is a real limitation that honest reporting on omega-3s has to mention.
Where the fatty acids actually go to work
EPA and DHA are not interchangeable, even though they are almost always bottled together under one label. EPA appears to have a more direct effect on triglycerides and inflammatory signaling, which is likely part of why the EPA-only REDUCE-IT trial produced a larger cardiovascular signal than mixed-formula trials like VITAL.
DHA makes up a large share of the fatty acid content in the brain and retina, and is the form most consistently linked to fetal neurological development during pregnancy. Both fatty acids get converted in the body into signaling molecules called resolvins and protectins, compounds that actively shut down inflammation rather than simply blocking it, a distinct mechanism from most anti-inflammatory drugs.
This resolution pathway, first mapped in detail by researchers at Harvard Medical School, is one reason omega-3s continue to be studied for conditions well beyond the heart, from joint pain to mood disorders.
The clearest, least disputed benefit
Strip away the cardiovascular debate and one effect of omega-3 supplementation is consistently reproducible: it lowers triglycerides. High-dose EPA and DHA can reduce triglyceride levels by 20 to 30 percent in people who start out elevated, an effect strong enough that prescription-strength omega-3 formulations are FDA-approved specifically for that purpose.
There is also emerging evidence for muscle. Research on omega-3 supplementation in older adults has found it can modestly increase the rate of muscle protein synthesis in response to a meal, a mechanism that may help explain why fish oil is being studied as a tool against age-related muscle loss.
That effect is smaller and less consistent than the triglyceride finding, and it has not been tested at the scale of a REDUCE-IT or VITAL. It has, however, renewed interest in omega-3s among researchers who study aging and recovery, not just cardiology.
Why blood levels matter more than the label
Part of why trials disagree is that a fixed dose does not produce a fixed blood level. Two people taking the same 1,000 milligram capsule can end up with very different amounts of EPA and DHA circulating in their red blood cells, depending on diet, genetics, and how much omega-6 fat they otherwise eat.
William Harris, a researcher who helped develop the Omega-3 Index, a blood test that measures EPA and DHA as a percentage of total red blood cell fatty acids, has argued that dosing by a fixed milligram number without checking blood levels is part of why some trials wash out. An index above 8 percent is associated with lower cardiovascular risk in observational research, while most Americans test below 4 percent.
That test is not something most people will ever order, but it explains why a label that reads 1,000mg a day is a weaker instruction than it sounds. The same dose can land two different people in very different places.
What this means before you reach for a bottle
None of this means fish oil is worthless, and none of it means it is a guaranteed fix for heart risk. The honest read of the evidence is that omega-3s do one thing very reliably, lowering triglycerides, and several other things plausibly but with weaker, more dose-dependent evidence behind them.
For most healthy adults already eating fatty fish once or twice a week, the marginal benefit of an added supplement is likely small. For someone with elevated triglycerides, existing heart disease, or a diet with almost no fish, the case is considerably stronger, and worth an actual conversation with a physician about dose rather than just a trip to the supplement aisle.
The omega-3 story was never really about whether fish oil works. It was always about how much, in what form, and for whom, questions that a bottle with a single dosage on the label was never built to answer.
